Liquidia (LQDA) EBITDA Margin Growth (1y) (2021 - 2026)
Powered by 
Analysis
Liquidia (LQDA) EBITDA Margin Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.53 Bn | 625.77 Bn | 17.26 Bn | 22.00 |
| 2 | AbbVie | 442.27 Bn | 435.70 Bn | 12.70 Bn | 613.00 |
| 3 | Merck | 366.81 Bn | 359.67 Bn | 12.21 Bn | -3,510.00 |
| 4 | Novartis Ag | 266.82 Bn | 259.13 Bn | 11.24 Bn | -164.00 |
| 5 | Pfizer | 159.37 Bn | 147.67 Bn | 10.94 Bn | -611.00 |
| 6 | Sanofi | 52.46 Bn | 45.08 Bn | 10.79 Bn | -572.00 |
| 7 | Revolution Medicines | 44.12 Bn | 44.12 Bn | - | - |
| 8 | Incyte | 25.49 Bn | 20.95 Bn | 1.57 Bn | -194.00 |
| 9 | United Therapeutics | 21.55 Bn | 18.89 Bn | 683.80 Mn | -341.00 |
| 10 | Liquidia | 6.09 Bn | 5.80 Bn | 160.92 Mn | 47,422.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 47,422.00 |
| Mar 31, 2026 | 118,171.00 |
| Dec 31, 2025 | 125,932.00 |
| Sep 30, 2025 | 65,948.00 |
| Jun 30, 2025 | 31,888.00 |
| Mar 31, 2025 | -16,634.00 |
| Dec 31, 2024 | -65,437.00 |
| Sep 30, 2024 | -25,136.00 |
| Jun 30, 2024 | -26,638.00 |
| Mar 31, 2024 | -76,360.00 |
| Dec 31, 2023 | -46,223.00 |
| Sep 30, 2023 | -12,585.00 |
| Jun 30, 2023 | -24,797.00 |
| Mar 31, 2023 | 20,896.00 |
| Dec 31, 2022 | 23,219.00 |
| Sep 30, 2022 | -5,631.00 |
| Jun 30, 2022 | -4,073.00 |
| Mar 31, 2022 | -12,257.00 |
| Dec 31, 2021 | 179,816.00 |